Johnson & Johnson's TECVAYLI-Daratumumab Combo Wins EU Approval For Relapsed Myeloma

The European Commission approved Johnson & Johnson's Tecvayli-Darzalex combo for treating relapsed or refractory multiple myeloma. LIB Therapeutics expanded Lerochol's approval for autoinjector use. Ono Pharmaceutical gained U.K. approval for Romvimza. Akeso's ivonescimab received Chinese approval for first-line squamous NSCLC. Eli Lilly's Foundayo got U.K. approval for weight management and Type 2 diabetes. AstraZeneca and Daiichi Sankyo's Enhertu approved in China for HER2-positive breast canc

The European Commission approved Johnson & Johnson's TECVAYLI® (teclistamab) combined with daratumumab for treating relapsed/refractory multiple myeloma. The approval, based on Phase 3 study data, shows significant improvements in progression-free and overall survival. The combination therapy demonstrated an 83.4% reduction in disease progression or death risk compared to standard care. Johnson & Johnson highlights the potential to redefine treatment standards for this patient group.

Johnson & Johnson (JNJ) reported operational sales growth led by its Innovative Medicine and MedTech businesses, raised its full-year outlook, and secured FDA clearance for MONARCH QUEST 3 AI-enabled bronchoscopy software. The company aims for $120.5B revenue and $28.6B earnings by 2029, with 7.2% yearly revenue growth. Analysts note MedTech's potential growth but highlight risks like talc litigation and biosimilar pressure.

Johnson & Johnson received U.S. regulatory clearance for MONARCH QUEST 3, a software update for its robotically-assisted bronchoscopy platform. The update enhances planning, navigation, and targeting capabilities, leveraging AI and expanding imaging integration. The company aims to improve procedural confidence and precision for clinicians. JNJ has launched three updates in 18 months, demonstrating its commitment to innovation in this area.

Moderna and Merck's experimental cancer vaccine showed promising Phase 3 results, preventing melanoma recurrence in certain patients. This drove significant stock price increases for both companies and other biopharma stocks, including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and BioNTech. Moderna's shares surged 138%, while Merck's rose 12.4%. The broader biopharma sector has been on an upswing, with investors rotating away from tech stocks. President Trump's nomination of a new FDA commiss

Johnson & Johnson (JNJ) reached a record high of $275.48, with a market cap of $661 billion. Its stock rose 53% over the past year, driven by Q2 revenue growth of 6.6% to $25.31 billion and adjusted EPS of $2.90. The company raised its 2026 revenue forecast to $101.1 billion. Analysts upgraded price targets, including Guggenheim's $287 projection.